Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.01.23.634441

Unmasking Epstein-Barr Role in Gastric Carcinogenesis: A Gene Expression Approach to Virus-Positive Tumors

Abstract

Human gammaherpesvirus 4 or Epstein-Barr virus (EBV) is an oncogenic virus linked to malignancies like gastric adenocarcinoma. Notably, EBV infection induces genetic and epigenetic modifications that play a crucial role in oncogenesis and tumor progression, underscoring the importance of analyzing viral gene expression in the context of gastric cancer (GC) to elucidate its unique characteristics. This study aimed to perform a molecular characterization of EBV gene expression using next-generation sequencing (NGS). The analysis included human gene expression patterns in EBV-positive and EBV-negative samples and the expression of viral genes in EBV-positive samples. The study received approval from the Ethics and Research Committee of Joao de Barros Barreto University Hospital under reference number 47580121.9.0000.5634. It utilized 76 tumor tissue samples from patients with gastric cancer who had undergone surgical resection, and both fresh and paraffin-embedded samples were gathered for total RNA sequencing (RNA-seq) and in situ hybridization (ISH). The RNA-seq was conducted in a pair-end manner on the NextSeq(R) platform (Illumina(R), US). The NextSeq(R) 500 MID Output V2 kit - 150 cycles (Illumina(R)) were utilized following the manufacturers instructions. ISH targeting RNA-1 of EBER1 (Y5200, DAKO, Carpinteria) was performed using the automated Dako system. Molecular characterization was conducted using the Kraken2 software. Subsequently, to elucidate the mechanisms through which EBV may influence gastric cancer, we analyzed the patterns of human gene expression in EBV-positive and EBV-negative samples. Of the 76 samples, 8 were classified as EBV-positive according to the applied methodology. Our analysis identified approximately 834 differentially expressed genes, 92 of which exhibited an AUC > 0.85. These genes are implicated in tumor progression, cellular metabolism, and both innate and adaptive immune responses. Additionally, viral genes expressed in the positive samples were evaluated, and we found manifestations of both lytic phase and latent phase genes. Finally, our study presents an efficient strategy for molecular classification of EBV-positive gastric cancer based on NGS and shows the effects of EBV on human gene expression. Author summaryIn our study, we explored how EBV influences the development of stomach cancer. EBV is a virus known to be linked to various cancers, including gastric cancer, and it can alter the behavior of both human and viral genes within infected cells. To investigate this, we analyzed tissue samples from 76 patients with stomach cancer, focusing on differences between samples with and without EBV. Using advanced sequencing technology, we identified over 800 genes that behave differently in EBV-positive cancers. These genes are involved in critical processes like how cells grow, how the immune system responds, and how energy is produced within cells. We also examined which EBV genes were active in the cancer samples and found evidence of both dormant and active phases of the virus. Our work demonstrated how EBV may contribute to stomach cancer and suggests new ways to classify and understand this disease. By uncovering these details, we hope to pave the way for more targeted treatments in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Santos da Silva, V. C., Pereira, D., Avelar, D. d. S., Silva, J. M. C. d., Mourao, R. M. d. S., Silva, R. F. d., Marcon, D. J., Magalhaes, L., Vidal, A. F., Neotti, T., Anaissi, A. K. M., Barra, W. F., Casseb, S. M., Ribeiro dos Santos, A. K. C., Demachki, S., Ishak, G., Assumpcao, P. P. d., Moreira, F., Burbano, R. M. R.. 2025-01-26. Unmasking Epstein-Barr Role in Gastric Carcinogenesis: A Gene Expression Approach to Virus-Positive Tumors. https://doi.org/10.1101/2025.01.23.634441

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sisyphus at the splenic flexure: sidedness in colorectal cancer

Colorectal cancer is divided into left and right to guide prognosis and therapy, yet a precise definition of left vs right sided colorectal cancer is still not fully agreed upon. The published conventions place it anywhere between the cecum and the rectosigmoid junction. The dichotomy assumes side homogeneity, i.e., that colorectal subsites within a side add limited information once the side is known. That assumption has been examined primarily through mutation prevalence, a quantity that confounds how often a driver arises with how strongly it is selected once it has. Analyzing 1,027 whole-exome and whole-genome sequenced colorectal tumors, we decomposed the prevalence of six driver groups into mutation supply and cancer effect, and asked whether a binary side label captures how each of their prevalence, mutation supply, and cancer effect vary along the colorectum. Mostly it does: the mutational input behaves as two blocks, and even the more than thirty-fold strengthening of cancer effect on BRAF V600E from sigmoid colon to cecum is adequately captured by side. But APC shows nominal evidence against side homogeneity in both prevalence and cancer effect while showing little net left-right difference, and PIK3CA H1047 rejects it in supply. The evidence for finer resolution is real but partial, and the failures do not announce themselves. We recommend additional research recording primary tumor location at the finest practicable resolution--at minimum, International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography. Such well-annotated datasets would enable the left-right boundary to be a reversible analytic choice rather than an irreversible annotation.

cancer biology↗

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

cancer biology↗

SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma

Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.

cancer biology↗